94 related articles for article (PubMed ID: 19943771)
1. The role of fibrinolytic and antifibrinolytic activities in the pathophysiology of HELLP syndrome.
Guven S; Sonmez M; Karahan SC
Hypertens Pregnancy; 2011; 30(3):275-86. PubMed ID: 19943771
[TBL] [Abstract][Full Text] [Related]
2. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
Oral B; Mermi B; Dilek M; Alanoğlu G; Sütçü R
Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
[TBL] [Abstract][Full Text] [Related]
3. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium.
Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
Agents Actions Suppl; 1992; 38 ( Pt 2)():320-9. PubMed ID: 1462839
[TBL] [Abstract][Full Text] [Related]
4. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
Akinci B; Demir T; Saygili S; Yener S; Alacacioglu I; Saygili F; Bayraktar F; Yesil S
Diabetes Res Clin Pract; 2008 Jul; 81(1):93-6. PubMed ID: 18406001
[TBL] [Abstract][Full Text] [Related]
5. Studies of blood coagulation-fibrinolysis regarding kallikrein-kinin system in severe preeclampsia.
Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
Agents Actions Suppl; 1992; 38 ( Pt 2)():342-9. PubMed ID: 1462840
[TBL] [Abstract][Full Text] [Related]
6. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
Ozeren M; Karahan SC; Ozgur M; Eminagaoglu S; Unsal M; Baytan S; Bozkaya H
Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
[TBL] [Abstract][Full Text] [Related]
7. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
8. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
9. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Shantsila E; Montoro-García S; Tapp LD; Apostolakis S; Wrigley BJ; Lip GY
Thromb Haemost; 2012 Jul; 108(1):32-40. PubMed ID: 22538774
[TBL] [Abstract][Full Text] [Related]
11. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.
Sartorio A; Cattaneo M; Bucciarelli P; Bottasso B; Porretti S; Epaminonda P; Faglia G; Arosio M
Exp Clin Endocrinol Diabetes; 2000; 108(7):486-92. PubMed ID: 11083070
[TBL] [Abstract][Full Text] [Related]
12. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
13. Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1.
de Moerloose P; Mermillod N; Amiral J; Reber G
Thromb Haemost; 1998 Mar; 79(3):554-6. PubMed ID: 9531039
[TBL] [Abstract][Full Text] [Related]
14. The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis.
Reddick KL; Smrtka MP; Grotegut CA; James AH; Brancazio LR; Swamy GK
Am J Perinatol; 2014 Oct; 31(9):735-40. PubMed ID: 24338119
[TBL] [Abstract][Full Text] [Related]
15. [Changes in fibrinolysis-associated parameters in HELLP syndrome].
Kolben M; Lopens A; Schmitt M; Schneider KT; Graeff H
Geburtshilfe Frauenheilkd; 1994 May; 54(5):257-61. PubMed ID: 8050684
[TBL] [Abstract][Full Text] [Related]
16. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
[TBL] [Abstract][Full Text] [Related]
17. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Mehta P; Parker RI
J Pediatr Hematol Oncol; 2010 Oct; 32(7):532-6. PubMed ID: 20686427
[TBL] [Abstract][Full Text] [Related]
18. TAFI and PAI-1 levels in human sepsis.
Zeerleder S; Schroeder V; Hack CE; Kohler HP; Wuillemin WA
Thromb Res; 2006; 118(2):205-12. PubMed ID: 16009400
[TBL] [Abstract][Full Text] [Related]
19. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
20. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D
Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]